Stealth BioTherapeutics announced the appointment of Mark P. Colonnese as Chief Financial Officer. In this role at Stealth, Mr. Colonnese will lead the company's financial and capital markets strategy, as well as advise on business development and transactional activities. Prior to joining Stealth, Mr. Colonnese most recently served as Executive Vice President and Chief Financial Officer at Transgenomic, Inc.
Stealth BioTherapeutics Corp
Equities
MITO
US85789A1051
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+54.05% | 58.71B | |
-2.02% | 41.31B | |
+36.98% | 39.2B | |
-10.22% | 27.4B | |
+13.42% | 26.55B | |
-21.60% | 18.98B | |
+2.89% | 12.51B | |
+22.40% | 11.94B | |
+27.49% | 12.08B |